newswire, breaking biotechnology and pharma news

Wednesday, March 28, 2012

Medical Technology Stock Alert; PositiveID Corporation (OTCBB:PSID) Receives Nucleic Acids From the CDC Influenza Division to Develop a Diagnostic Assay to Detect H5N1 Avian Flu

DELRAY BEACH, Fla. - March 28, 2012 ( newswire) - PositiveID Corporation (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense industry, announced today that it has received material from the U.S. Centers for Disease Control and Prevention's (CDC) Influenza Division-National Center for Immunization and Respiratory Diseases to develop a diagnostic assay to detect Influenza A H5N1, also known as avian flu. This assay will provide a test result in less than 30 minutes at the point of care, and is expected to be available for the upcoming flu season for diagnostic and surveillance applications.

The United Nations has urged people to be ready against a possible but major resurgence of the avian flu. According to the CDC, of the few avian influenza viruses that have crossed the species barrier to infect humans, the mutant strain of bird flu has caused the largest number of detected cases of severe disease and death in humans. Human cases of avian influenza A (H5N1) have been reported in Asia, Africa, Europe, Indonesia, Vietnam, the Pacific, and the near East. Slightly more than 60 percent of those who became ill have died.

PositiveID's assay for avian flu, as well as its other currently available assays, will run on the Company's patented Dragonfly Rapid MDx platform. Dragonfly was created out of the Company's M-BAND system, which was developed under contract from the Department of Homeland Security. The H5N1 assay will also be compatible with other commercial platforms.

The Company currently has proven assays for E.coli O157:H7; human papilloma virus (HPV); methicillin-resistant Staphylococcus aureus (MRSA); and a multiplex bio-threat assay that simultaneously tests for six bio-threat organisms on the CDC Category A and B list.

The development of an H5N1 assay is the Company's most recent push into the clinical diagnostics market, where it will offer faster, less expensive testing methods than those that are commonly used.

William J. Caragol, Chairman and CEO of PositiveID, stated, "Our assay for H5N1, as well as our other clinical diagnostic assays, will be faster and less expensive than the industry standard testing protocol. Furthermore, our microfluidic technology is highly adaptable, which enables us to develop new assays for emerging bio-threats and viruses relatively quickly, which we believe will help us as we enter the clinical diagnostic market."

About PositiveID Corporation OTCBB:PSID)

PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit

Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.


Allison Tomek

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on
Visit the company profile:

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: and disclosures:
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

No comments:

Post a Comment